COVID-19 Data Review: Update on COVID-19–Related Mortality – CDC

COVID-19 Data Reviews provide timely updates and share preliminary results of analyses that can improve the understanding of the pandemic and inform further scientific inquiry. COVID-19 Data Reviews reflect the scientific evidence on a specific topic at the time of the report’s publication. As scientific evidence and available information on COVID-19 change, COVID-19 Data Reviews will be systematically archived as historic reference materials.
As of November 9, 2022, 1,070,947 COVID-19-related deaths have been reported in the United States.1 In the first two years of the pandemic, COVID-19 was identified as the third leading cause of death in the United States, trailing only heart disease and cancer.2, 3 Provisional mortality data indicate that, despite a lower number of COVID-19–related deaths reported to date in 2022, COVID-19 remains the third leading cause of death in the United States.3
Several factors have led to changing patterns of COVID-19 morbidity and mortality over the course of the pandemic, including the introduction and widespread availability of COVID-19 vaccines, high population prevalence of infection-induced immunity, increased availability of effective COVID-19 outpatient treatment, and changes in the SARS-CoV-2 virus itself. In this report, we provide an overview of COVID-19–related mortality in the United States as of November 9, 2022. In addition to overall trends, we present detailed analysis of recent trends during which Omicron subvariants have been the predominant circulating SARS-CoV-2 strains.
Throughout the pandemic, CDC has provided information on COVID-19–related mortality, including through data provided on COVID Data Tracker and scientific publications. This report builds on previous work and contains preliminary results, as well as pertinent data from previously published analyses, that can improve understanding of COVID-19–related deaths, drive public health action, and inform further scientific inquiry. Findings from several data sources are presented to provide a comprehensive and timely overview of COVID-19–related mortality in the United States. This report is intended for scientific and public health professionals, however, the information provided could be of use to other groups and the public. Additional information about the status of the pandemic, mortality data, guidance, and information for the general public can be accessed via
In this report, we examine trends in COVID-19–related mortality and ask the following questions:
The data presented in this report show a rapid reduction in the overall U.S. COVID-19–related mortality rate in March 2022. From April through September 2022, COVID-19–related mortality rates remained relatively stable; to date, this has been the longest interval during the pandemic in which the COVID-19–related mortality rate was <22 deaths per 100,000 population for all age groups. However, during this period, 2,000–4,500 COVID-19–related deaths were reported weekly. Further, a higher number of overall (all-cause) deaths occurred compared to the number that would be expected based on previous years of data (excess deaths).
Although overall COVID-19–related mortality rates declined, adults aged ≥65 years continued to have the highest mortality rates. During April–September 2022, the proportion of COVID-19–related deaths accounted for by adults aged ≥85 years increased to ~40% despite accounting for <2% of the U.S. population. COVID-19–related deaths among children remained rare. Although racial and ethnic disparities in COVID-19–related mortality have decreased over the course of the pandemic, disparities persisted. COVID-19 vaccines continued to reduce the risk of dying from COVID-19 among all adult age groups, including adults aged ≥65 years, with the greatest protection observed among older adults who received ≥2 booster doses.
COVID-19 was reported as the underlying cause of death for most COVID-19–related deaths. However, a higher proportion of COVID-19–related deaths had COVID-19 listed as a contributing cause of death during January–September 2022 compared to previous years of the pandemic. This finding was observed among persons dying in hospitals and, to a greater extent, in non-hospital settings such as long-term care facilities and hospice facilities, where a higher proportion of COVID-19–related deaths occurred than earlier in the pandemic. The reasons for these changes are unclear but might signal that 1) people who died outside of the hospital had other health conditions where the severity of those conditions was exacerbated by having COVID-19; 2) people infected with SARS-CoV-2 might have been hospitalized for another condition, but COVID-19 contributed to their death; or 3) that people who survived infection with SARS-CoV-2 continued to suffer COVID-19–related long-term health effects that contributed to their death.
Risk of dying while hospitalized for COVID-19 declined steeply during March–April 2022 and remained lower through August 2022 compared to rates observed during June 2021–February 2022. Risk of in-hospital death was highest for patients hospitalized for COVID-19 with ≥5 underlying medical conditions, patients with disabilities, and patients aged ≥80 years. In-hospital death among persons aged 18–49 years hospitalized with COVID-19 during May–August 2022 was rare (1% of COVID-19–associated hospitalizations); most of these patients were unvaccinated. The proportion of patients hospitalized primarily for COVID-19 that had an indicator of severe disease (e.g., required intensive medical intervention) also declined. Less severe COVID-19 disease among hospitalized patients could contribute to the lower rate of in-hospital deaths observed. Decreased use of intensive medical interventions among patients who died in-hospital with COVID-19 could also reflect the increased occurrence of deaths among older people with multiple comorbidities who might not have tolerated or benefited from such interventions or, who did not agree to intensive medical intervention.
Early treatment with COVID-19 medication can reduce the risk of COVID-19–related hospitalization and mortality among patients at risk for severe COVID-19.4-7 Use of outpatient COVID-19 treatment increased in 2022, particularly during April–July 2022 when nirmatrelvir/ritonavir (Paxlovid), an oral antiviral medication, became widely available. During this period, Paxlovid was the most commonly used outpatient COVID-19 medication among all age groups, with some differences in use by patient age, race and ethnicity, and type of immunocompromising condition.
Data in this report are provided from multiple data sources to understand recent mortality trends. Variation across data sources in the time ranges presented are due to differences in data availability and reporting frequency, with the most recently available data ranging from June 2022 to November 2022 (see Data Source Notes for additional information). Due to differences in data collection methods, patient populations covered, variation in the hospitals and/or jurisdictions included in data systems, completeness of reporting, and availability of demographic or geographic information, all reported results may not be generalizable to the entire U.S. population. Additionally, there is variation in how event-based data are organized by date (e.g., event date compared to report date) across data sources. Most analyses include only descriptive results and do not control for confounding nor statistically assess trends or associations. Therefore, comparisons across populations, time, and data sets should be interpreted with caution.
1. There were signs of improvement
2. Vaccines continued to be effective in reducing COVID-19–related mortality
3. Where and how COVID-19–related deaths occur appeared to be changing
4. Improvement is needed to decrease risk for COVID-19–related mortality
To receive email updates about COVID-19, enter your email address:
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.